ELTX Stock Summary and Trading Ideas (Elicio Therapeutics | NASDAQ:ELTX)

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Elicio Therapeutics trades on the NASDAQ stock market under the symbol ELTX.

As of August 17, 2026, ELTX stock price declined to $3.01 with 234,025 million shares trading.

ELTX has a beta of 0.54, meaning it tends to be less sensitive to market movements. ELTX has a correlation of 0.00 to the broad based SPY ETF.

ELTX has a market cap of $79.06 million. This is considered a Micro Cap stock.

In the last 3 years, ELTX traded as high as $16.00 and as low as $2.66.

The top ETF exchange traded funds that ELTX belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

ELTX has underperformed the market in the last year with a return of -69.7%, while the SPY ETF gained +21.0%. In the last 3 month period, ELTX fell short of the market, returning -72.4%, while SPY returned +3.6%. However, in the most recent 2 weeks ELTX has outperformed the stock market by returning +7.5%, while SPY returned +3.5%.

ELTX support price is $2.95 and resistance is $3.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELTX shares will trade within this expected range on the day.